12 High Growth Large Cap Stocks to Buy Now

2) Moderna, Inc. (NASDAQ:MRNA)

5-Year Revenue Growth: ~128.5%

Average Upside Potential: ~67.9%

Market cap as of 12 November: $16.6 billion

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company, that discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases.

One of Moderna, Inc. (NASDAQ:MRNA)’s key focus areas for growth is the respiratory syncytial virus (RSV) vaccine, mRESVIA. The US FDA approved mRESVIA in 2024. Moving forward, the company remains focused on fueling sales growth and reducing its cost structure. Moderna, Inc. (NASDAQ:MRNA)’s future growth potential stems from its diverse pipeline of mRNA-based therapeutics and vaccines. Its mRNA-4157, in combination with Merck’s Keytruda, demonstrated promising results in early-stage trials for melanoma and head and neck squamous cell carcinoma.

Moderna, Inc. (NASDAQ:MRNA)’s investigational therapeutic for MMA (mRNA-3705) was selected by the U.S. FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. The FDA and the company have agreed on the pivotal study design. Moderna, Inc. (NASDAQ:MRNA) anticipates to start a pivotal study in H1 2025.

Wall Street analysts are quite optimistic about a joint agreement with Cenra Healthcare to promote Moderna’s mRNA respiratory vaccine portfolio in Taiwan, which includes COVID-19 vaccines. Cenra’s strong presence in the market should help ensure broader access to Moderna, Inc. (NASDAQ:MRNA)’s vaccines. This partnership will enable it to expand its future portfolio, primarily as respiratory diseases are posing a global threat.

Moderna, Inc. (NASDAQ:MRNA)’s progress in cancer vaccines, mainly the combination of mRNA-4157 with Keytruda, reflects promise in catering to significant unmet medical needs. The company’s work on combination vaccines, like the Flu+COVID vaccine, might offer a competitive edge in the evolving vaccine landscape. Its broad pipeline, such as candidates for CMV, norovirus, and other indications, should translate into multiple avenues for future growth and revenue diversification.

As per Wall Street analysts, the shares of Moderna, Inc. (NASDAQ:MRNA) have an average target price of $87.71.